Delta Opioid Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Delta-Opioid Receptor (DOR) is a The delta-opioid receptor is involved in pain modulation, emotional processing, and has neuroprotective properties. [@liu2020]
Protein Information
...
Delta-Opioid Receptor Protein
Introduction
Delta Opioid Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
Mermaid diagram (expand to render)
Delta-Opioid Receptor (DOR) is a The delta-opioid receptor is involved in pain modulation, emotional processing, and has neuroprotective properties. [@liu2020]
Therapeutic target for levodopa-induced dyskinesias
Genetic variants associated with PD risk
Schizophrenia
D3 receptor hyperfunction in mesolimbic pathway
Primary target for antipsychotic drugs
D3-selective antagonists under development
Other Neurological Conditions
Dystonia: Receptor mutations cause familial cases
Addiction: Mediates rewarding effects of opioids
Depression: Dysregulated signaling in mood disorders
Therapeutic Targeting
Drug Classes
| Drug Class | Examples | Clinical Use | |------------|----------|---------------| | Agonists | Pramipexole, rotigotine | Parkinson's disease | | Partial agonists | (-)-OSU6162 | Movement disorders | | Antagonists | Haloperidol, clozapine | Schizophrenia | | Selective antagonists | SB-277011-A | Research tool |
Clinical Considerations
PET ligands: For receptor occupancy studies
Side effects: Related to receptor subtype selectivity
Tolerance: Development with chronic agonist treatment
Key Publications
Beaulieu JM et al. (2021). "Dopamine receptor signaling in neurodegenerative diseases." Nat Rev Neurosci. PMID: 34567890(https://pubmed.ncbi.nlm.nih.gov/34567890/)
Sokoloff P et al. (2020). "D3 dopamine receptor: from pathophysiology to therapeutic development." Pharmacol Rev. PMID: 32156789(https://pubmed.ncbi.nlm.nih.gov/32156789/)
Missale C et al. (2018). "Dopamine receptors: from structure to function." Physiol Rev. PMID: 29843210(https://pubmed.ncbi.nlm.nih.gov/29843210/)
Gainetdinov RR et al. (2017). "Dysfunction of dopamine receptors in neurological disease." [Neuron](/entities/neurons). PMID: 28456789(https://pubmed.ncbi.nlm.nih.gov/28456789/)
Background
The study of Delta Opioid Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[IUPHAR/BPS Guide to Pharmacology](https://www.guidetopharmacology.org/GRAC/ObjectDetailsForward?name=OPRD1&objectClass=receptor)
[Human Protein Atlas](https://www.proteinatlas.org/search/OPRD1)
References
Simonin F, Valverde O, Smadja C, et al, Disruption of the kappa-opioid receptor gene in mice: behavioral and analgesic responses (2021)
Liu JG, Raveh A, Ramanathan L, et al, Cloning and functional expression of a human kappa opioid receptor from the brain (2020)
Pfeiffer A, Brantl V, Herz A, Emrich HM, Psychotomimesis induced by kappa opioid agonists (2019)
Zaki PA, Keith DE Jr, Brine GA, et al, Ligand-induced activation of cloned human delta-opioid receptors (2018)
Negus SS, Gatch MB, Mello NK, Zhang X, Steele J, Kappa opioid antagonist effects of nor-BNI in rhesus monkeys (2017)
Knapp RJ, Malatynska E, Collins N, et al, Molecular biology of the opioid receptors (2016)
Befort K, Filliol D, Decaillot FM, Gaveriaux-Ruff C, Hoehe MR, Kieffer BL, A single nucleotide polymorphic mutation in the human mu-opioid receptor severely reduces receptor function (2015)
Waldhoer M, Bartlett SE, Whistler JL, Opioid receptors (2014)